Merck & Co. has scored an FDA approval for its blockbuster-to-be Welireg to move into second-line treatment of kidney cancer, ...
This marks the third ccRCC approval for the hypoxia-inducible factor-2-alpha inhibitor belzutifan. Its previous approvals ...
Clear cell renal cell carcinoma, the most common and most lethal form of kidney cancer, has long frustrated oncologists with ...
Yesterday, September 24, the FDA approved the combination of belzutifan (WELIREG; Merck) plus lenvatinib (LENVIMA; Eisai) to ...
Researchers developed an AI framework that identified tissue components, classified nine renal cell tumor subtypes, predicted nuclear grade, and stratified survival across multicenter cohorts. The ...
Belzutifan plus lenvatinib significantly improves progression-free survival in advanced renal cell carcinoma. Read more on ...
Renal cell carcinoma is the most common form of kidney cancer. It can take time to fully process a diagnosis and what, exactly, it may mean. Developing a good understanding of your disease—and ...
Free Malaysia Today on MSN
Kidney cancer is often silent – until it isn’t
Early tumours may cause few or no symptoms, making routine screening especially important for timely treatment.
Papillary renal cell carcinoma (PRCC) is a type of kidney cancer. It starts in the small tubes in the kidneys that filter waste from the blood. PRCC may be Type 1 or Type 2, which can affect the ...
Cancer fighting T cells, the immune system’s primary enforcers, are scarce in the rare kidney cancer called chromophobe renal cell carcinoma (ChRCC) and those that are present are indifferent to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results